DALLAS, June 25, 2009 -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Mr. Jeffrey Davis, Chief Executive Officer and Mr. David Luci, Director and Consultant, were recently interviewed by StocksHaven.com, a financial website. The hour-long call was to provide an executive summary, along with an overview and update of the Access Pharmaceuticals's business strategy. Mr. Davis shed light on acquisitions, partnerships, current and future plans, and also discussed preparations to re-rejoin a major exchange. The interview is currently featured on the website at http://www.stockshaven.com/.
"We are pleased to be featured by StocksHaven Investments," commented Mr. Davis. "As we continue to build upon our business, now is an opportune time to learn about Access and we are glad to share our exciting investment thesis with financial websites that offer investors new and upcoming investment ideas."
About StocksHaven.com
StocksHaven.com is a website which hosts services for StocksHaven Investments. The website contains a blog, free level 2 quotes, discussion forum, stock research reports, conference calls, investment dictionary, news feeds, videos, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Report on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
"We are pleased to be featured by StocksHaven Investments," commented Mr. Davis. "As we continue to build upon our business, now is an opportune time to learn about Access and we are glad to share our exciting investment thesis with financial websites that offer investors new and upcoming investment ideas."
About StocksHaven.com
StocksHaven.com is a website which hosts services for StocksHaven Investments. The website contains a blog, free level 2 quotes, discussion forum, stock research reports, conference calls, investment dictionary, news feeds, videos, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Report on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.